Selective neuronal damage and blood pressure in atherosclerotic major cerebral artery disease

Hiroshi Yamauchi, Shinya Kagawa, Masaaki Takahashi, Kuninori Kusano, Chio Okuyama

Division of PET Imaging, Shiga Medical Center Research Institute, Moriyama, Japan
Correspondence to
Dr Hiroshi Yamauchi, Division of PET Imaging, Shiga Medical Center Research Institute, Moriyama, S24 8524, Japan; yamauchi@kuhp.kyoto-u.ac.jp

Received 3 January 2019
Revised 2 April 2019
Accepted 5 April 2019
Published Online First 24 May 2019

ABSTRACT
Objective In patients with atherosclerotic major cerebral artery disease, low blood pressure might impair cerebral perfusion, thereby exacerbate the risk of selective neuronal damage. The purpose of this retrospective study was to determine whether low blood pressure at follow-up is associated with increased selective neuronal damage.

Methods We retrospectively analysed data from 76 medically treated patients with atherosclerotic internal carotid artery or middle cerebral artery disease with no ischaemic episodes on a follow-up of 6 months or more. All patients had measurements of the distribution of central benzodiazepine receptors twice using positron emission tomography and 11C-flumazenil. Using three-dimensional stereotactic surface projections, we quantified abnormal decreases in the benzodiazepine receptors of the cerebral cortex within the middle cerebral artery distribution and correlated these changes in the benzodiazepine receptors index with blood pressure values at follow-up examinations.

Results The changes in the benzodiazepine receptor index during follow-up (mean 27±2.1 months) were negatively correlated with systolic blood pressure at follow-up. The relationship between changes in benzodiazepine receptor index and systolic blood pressure was different among patients with and without decreased cerebral blood flow at baseline (interaction, p<0.005). Larger increases in benzodiazepine receptor index (neuronal damage) were observed at lower systolic blood pressure levels in patients with decreased cerebral blood flow than in patients without such decreases.

Conclusion In patients without ischaemic stroke episodes at follow-up but with decreased cerebral blood flow due to arterial disease, low systolic blood pressure at follow-up may be associated with increased selective neuronal damage.

INTRODUCTION
In patients with atherosclerotic internal carotid artery (ICA) or middle cerebral artery (MCA) disease, chronic reductions in cerebral perfusion pressure may increase their risk for cerebral ischaemic damage.1–4 Although severe ischaemia causes ischaemic stroke, ischaemia of moderate severity may cause selective neuronal damage.5–7 In patients with chronic haemodynamic impairment caused by atherosclerotic major cerebral artery disease, transient decreases in perfusion pressure may reduce perfusion below the penumbra threshold for minutes, which may cause selective neuronal damage without overt stroke.8–11 Low blood pressure (BP) might impair cerebral perfusion in patients with atherosclerotic major cerebral artery disease12 and thereby exacerbate the degree of haemodynamic impairment and the risk of selective neuronal damage in these individuals.2,13 Therefore, low BP at follow-up may be associated with a risk of selective neuronal damage during the follow-up period. However, no studies have investigated the relationship between BP and selective neuronal damage during this period. Given its association with cognitive impairment, selective neuronal damage may constitute an essential target for the treatment of patients with chronic haemodynamic impairment.14–16

Because most cortical neurons express central-type benzodiazepine receptors (BZRs), specific imaging of these receptors allows for in vivo visualisation of neuronal receptors alterations induced by ischaemia.17,18 For instance, selective neuronal damage can be detected in humans using positron emission tomography (PET) and 11C-flumazenil (FMZ), a ligand for BZRs.6,7 We retrospectively analysed the relationship between BP at follow-up and the changes in the BZRs during follow-up in patients with atherosclerotic ICA or MCA disease and no ischaemic stroke episodes during follow-up. The aim of this study was to determine whether low BP at follow-up is associated with increases in selective neuronal damage, evaluated as a decrease in BZRs.

SUBJECTS AND METHODS
Patients
In this study, we did a retrospective analysis of a prospectively collected data set investigating the relationship between changes in selective neuronal damage and haemodynamic impairment in patients with atherosclerotic ICA or MCA disease.8 We used 76 patients with a follow-up time of 6 months or more in these analyses (table 1). All patients were part of a previously published data set.8 We evaluated the distribution of BZRs in the brains of these patients twice using PET. Patients were referred to our PET unit for evaluation of the haemodynamic effects of ICA or MCA disease as part of a comprehensive clinical evaluation to determine whether they required vascular reconstruction surgery.

Inclusion criteria were as follows: (1) occlusion or stenosis of the ICA (>60% diameter reduction according to the North American Symptomatic Carotid Endarterectomy Trial criteria19) or MCA
PET measurements

We performed PET scans for each patient using an advance whole-body scanner (General Electric Medical Systems, Wauwatosa, Wisconsin), which allows for the simultaneous acquisition of 35 slice image with an interslice distance of 4.25 mm. After a transmission scan using germanium-68/gallium-68 (68Ge /68Ga), we performed a series of 15O-gas studies. We placed a small cannula in the left brachial artery for blood sampling. C15O2 and 15O2 were delivered continuously to the patient via a mask for the duration of the 5 min scan. Cerebral blood volume (CBV) was measured based on bolus inhalation of C15O via a 3 min scan. We obtained arterial samples manually during scanning. We measured the radioactivity of the radiotracer, oxygen content and haemocitric. We measured BP via an arterial catheter connected to a pressure transducer. Averaged BP values during C15O2 and 15O2 scanning were used as BP values on PET examinations and were used for the analysis in this study.

15O-gas studies were followed by 11C-FMZ studies. 11C-FMZ was synthesised by 11C-methylation of demethylated-FMZ (Hoffmann-La Roche, Basel, Switzerland). After intravenous injection of 370–555 MBq of 11C-FMZ into the right antecubital vein using an automatic injector for 60 s, a 50 min dynamic PET scan was initiated at the time of tracer administration.

We used the steady-state method to calculate cerebral blood flow (CBF), cerebral metabolic rate of oxygen (CMRO2) and oxygen extraction fraction (OEF). CMRO2 and OEF were corrected on the basis of CBV. We calculated the binding potential (BP) (non-displaceable) of 11C-FMZ using dynamic data and Logan graphical analysis with reference tissue, by using the time-activity curves obtained from the pons (the reference region).

To obtain normal control values for 15O-gas PET variables, we performed 15O-gas studies with arterial sampling across seven normal volunteers (four men and three women), aged 47±7 (mean±SD), who underwent normal routine neurological examinations and MRI scans.

Data analysis

We used a classical region-of-interest (ROI) approach to analyse 15O-gas PET scans. We analysed 10 tomographic planes from 46.25 to 84.5 mm above and parallel to the orbitomeatal line, which corresponded to the levels from the basal ganglia and thalami to the centrum semiovale. The ROI was placed on the CBF images. We then examined each image by placing a total of 10–12 circular ROIs 16 mm in diameter compactly over the grey matter of the outer cortex in each hemisphere. According to the atlas prepared by Kretschmann and Weinrich, we distributed the same ROIs to the other images. We then calculated the mean hemispheric value for the hemisphere affected by arterial disease as the average of all circular ROIs.

As previously described, we analysed the FMZ-BP parametric images with a three-dimensional stereotactic surface projection technique. This method anatomically normalised individual PET data to standard brain data. Pixels were located on the outer and medial surfaces of both hemispheres using a standard stereotactic system. The highest surface pixel value was compared between patients and controls. We normalised pixel values of an individual’s image set to the mean cerebellar value before examination. We calculated the Z-scores for each surface pixel (mean normalised pixel value for controls − normalised pixel value for the patient) / SD for controls) and used them to scale decreases

---

**Table 1 Patient characteristics**

| Characteristics                        | Number of patients | Age, years | Sex, male, n | Symptomatic (TIA/stroke), n | Cerebral ischaemic lesion, n | Qualifying artery, n | ICA (occlusion/stenosis), n | MCA (occlusion/stenosis), n | Other medical illness, n | Hypertension | Calcium antagonist | ACE inhibitor | ARB | Diabetes mellitus | Ischaemic heart disease | Hypercholesterolaemia | Cigarette use (current and former), n | Antiplatelet agent use | Statin use | Systolic blood pressure |
|----------------------------------------|--------------------|------------|--------------|---------------------------|-----------------------------|-------------------------|-------------------------|---------------------------|--------------------------|-------------|---------------------|-------------|-----|------------------|------------------------|------------------------|-----------------------------|-----------------------|-----------|---------------------|
| Number of patients                    | 76                 | 63±8       | 52           | 52 (17/35)                | 55                          | 41                      | 40 (30/10)              | 36 (27/9)                 | 41                       | 41          | 28                  | 5           | 21  | 19               | 23                     | 35                     | 27                           | 56                    | 27         | 143±19              |
| Interval, mean±SD (range), months     | 27±21 (6–108)      |            |              |                           |                             |                         |                         |                           |                          |             |                     |             |     |                  |                        |                        |                              |                       |           |                     |
| Age, years                            | 63±8               |            |              |                           |                             |                         |                         |                           |                          |             |                     |             |     |                  |                        |                        |                              |                       |           |                     |
| Sex, male, n                          | 52                 |            |              |                           |                             |                         |                         |                           |                          |             |                     |             |     |                  |                        |                        |                              |                       |           |                     |
| Symptomatic (TIA/stroke), n           | 52                 |            |              |                           |                             |                         |                         |                           |                          |             |                     |             |     |                  |                        |                        |                              |                       |           |                     |
| Cerebral ischaemic lesion, n          | 55                 |            |              |                           |                             |                         |                         |                           |                          |             |                     |             |     |                  |                        |                        |                              |                       |           |                     |
| Qualifying artery, n                  | 41                 |            |              |                           |                             |                         |                         |                           |                          |             |                     |             |     |                  |                        |                        |                              |                       |           |                     |
| ICA (occlusion/stenosis), n           | 40 (30/10)         |            |              |                           |                             |                         |                         |                           |                          |             |                     |             |     |                  |                        |                        |                              |                       |           |                     |
| MCA (occlusion/stenosis), n           | 36 (27/9)          |            |              |                           |                             |                         |                         |                           |                          |             |                     |             |     |                  |                        |                        |                              |                       |           |                     |
| Other medical illness, n              | 41                 |            |              |                           |                             |                         |                         |                           |                          |             |                     |             |     |                  |                        |                        |                              |                       |           |                     |
| Hypertension                          | 41                 |            |              |                           |                             |                         |                         |                           |                          |             |                     |             |     |                  |                        |                        |                              |                       |           |                     |
| Calcium antagonist                    | 28                 |            |              |                           |                             |                         |                         |                           |                          |             |                     |             |     |                  |                        |                        |                              |                       |           |                     |
| ACE inhibitor                         | 5                  |            |              |                           |                             |                         |                         |                           |                          |             |                     |             |     |                  |                        |                        |                              |                       |           |                     |
| ARB                                   | 21                 |            |              |                           |                             |                         |                         |                           |                          |             |                     |             |     |                  |                        |                        |                              |                       |           |                     |
| Diabetes mellitus                     | 19                 |            |              |                           |                             |                         |                         |                           |                          |             |                     |             |     |                  |                        |                        |                              |                       |           |                     |
| Ischaemic heart disease               | 23                 |            |              |                           |                             |                         |                         |                           |                          |             |                     |             |     |                  |                        |                        |                              |                       |           |                     |
| Hypercholesterolaemia                 | 35                 |            |              |                           |                             |                         |                         |                           |                          |             |                     |             |     |                  |                        |                        |                              |                       |           |                     |
| Cigarette use (current and former), n | 27                 |            |              |                           |                             |                         |                         |                           |                          |             |                     |             |     |                  |                        |                        |                              |                       |           |                     |
| Antiplatelet agent use                | 56                 |            |              |                           |                             |                         |                         |                           |                          |             |                     |             |     |                  |                        |                        |                              |                       |           |                     |
| Statin use                            | 27                 |            |              |                           |                             |                         |                         |                           |                          |             |                     |             |     |                  |                        |                        |                              |                       |           |                     |
| Systolic blood pressure               | 143±19             |            |              |                           |                             |                         |                         |                           |                          |             |                     |             |     |                  |                        |                        |                              |                       |           |                     |

AR, angiotensin receptor blocker; ICA, internal carotid artery; MCA, middle cerebral artery; TIA, transient ischaemic attack.

(>50% diameter reduction) as documented by conventional or magnetic resonance (MR) angiography; (2) functional independence in daily life (a modified Rankin Scale score <3); (3) for symptomatic patients, history of transient ischaemic attack (TIA) or minor completed stroke in ICA or MCA distribution; (4) medical treatment with no TIA or stroke since the first PET examination; (5) availability and willingness to return for follow-up PET examination; and (6) a follow-up time allowance of 6 months or more. TIA was defined as focal symptoms of presumed ischaemic cerebrovascular origin lasting <24 hours. Exclusion criteria were (1) infarction in the cerebral cortex, in the cerebellum or in the brainstem detectable on routine MRI (T1-weighted, T2-weighted or fluid-attenuated inversion recovery imaging) or CT imaging; (2) a history of vascular reconstruction surgery; (3) unilateral arterial disease with extensive white matter lesions in both hemispheres, likely caused by bilateral small vessel disease; (4) a history of BZR agonist use; and (5) the presence of potential sources of a cardiogenic embolism.

We evaluated patient status with respect to hypertension, diabetes mellitus, ischaemic heart disease, hypercholesterolaemia and smoking at the first PET examination. Hypertension, diabetes mellitus, ischaemic heart disease or hypercholesterolaemia was judged to be present when there was a history of treatment.

To establish a control database for BZR imaging, we also enrolled 10 healthy control subjects, aged 57±7 years, including 7 men and 3 women with no history of medical or psychiatric disorder or of taking BZR agonists. Among them, seven subjects, aged 56±8 years, including four men and three women, attended follow-up PET examinations. The interval between first examination and follow-up PET studies ranged from 38 to 45 months (mean 41±3 months).

To obtain normal control values for 15O-gas PET variables, we performed 15O-gas studies with arterial sampling across seven normal volunteers (four men and three women), aged 47±7 (mean±SD), who underwent normal routine neurological examinations and MRI scans.
in FMZ-BP. Therefore, a positive Z-score depicted a reduced FMZ-BP compared with the control group. To quantitate the degree of abnormal FMZ-BP reduction in each patient, we used the stereotactic extraction estimation method to compute the BZR index (defined as (% pixels with Z-score > 2) × (average Z-score for those pixels)) for the MCA distribution, as previously described.\(^{10, 28}\) An increased BZR index corresponds to a decreased BZR level, and thus greater cortical neuronal damage. The mean CBF value acquired among the 14 control hemispheres from seven healthy volunteers was 44.6±4.5 mL/100 g/min. We considered the hemispheric CBF values below the lower 95% limit (mean minus 1.645 SD) defined in healthy subjects (below 35.0 mL/100 g/min) to denote decreased CBF. On follow-up, we calculated the total change in the BZR index or the other PET variable values in the MCA distribution with arterial disease by deducing the values attained at the first examination from those acquired on follow-up examination. In controls, the calculation was carried out using the mean of the bilateral hemispheric values of the BZR index. The mean±SD value of changes in the index among controls was 0.94±1.38. In patients, an increase in the index beyond the upper 95% limit (the mean plus 1.645 SD), as defined in normal subjects (above 4.32), was considered to be an increased BZR index (indicating an increase in neuronal damage) at follow-up.

Statistical analysis
The statistical analysis was performed using StatView (SAS Institute, Cary, North Carolina, USA). We compared the clinical backgrounds or BZR index values between the two groups using a Student’s t-test or a Fisher’s exact test, as appropriate. We compared BZR index values between examinations using paired t-tests. Relationships between variables were analysed using simple or multiple regression analyses. Differences in the relationship between BP at follow-up and BZR index across subgroups (those with or without decreased CBF at baseline) were evaluated by analysis of covariance. For all analyses, statistical significance was considered to be p<0.05, unless stated otherwise.

RESULTS
Overall, the changes in the BZR index, CBF, OEF and systolic BP (SBP) during follow-up were 14.14±3.39, −0.41±6.73 mL/100 g/min, 1.28%±7.68%, and −5.1±21.7 mm Hg, respectively. Thirty-seven patients had an increased BZR index during follow-up.

After simple regression analysis, there was a significant negative linear relationship between changes in the BZR index and SBP at the follow-up PET examination (r=−0.238; p<0.05) (figures 1 and 2). SBP at the baseline examination was not correlated with changes in the BZR index.

Among patient characteristics (table 1), the interval between the first and follow-up PET studies was significantly correlated with changes in the BZR index (r=0.339; p<0.005), although patient age was not. We did not identify additional differences in changes in BZR index values between patients with and without male sex, symptom, cerebral ischaemic lesion, ICA disease, hypertension, diabetes mellitus, ischaemic heart disease, hypercholesterolaemia and cigarette use. No significant relationship was found between antihypertensive drug and changes in BZR index values.

Among PET haemodynamic variables at baseline, only CBF was significantly correlated with changes in the BZR index (r=−0.295; p<0.01). At follow-up, patients with decreased CBF values at baseline (n=39) showed a significant increase in the BZR index in the hemisphere with arterial disease, but not in the contralateral hemisphere (table 2). Patients without decreased CBF values at baseline (n=37) did not show significant changes in the BZR index in any hemispheres. Changes in the BZR index in the ipsilateral hemisphere among patients with decreased CBF values were significantly larger than those in patients without decreases.

Multivariable linear regression analysis was used to investigate the association of changes in the BZR index with (1) CBF at baseline, (2) SBP at follow-up, and (3) the interval between the first and follow-up PET studies (table 3). Our analysis produced a model that included these three independent variables with a correlation coefficient of 0.518 for the changes in the BZR index (p<0.001). In our model, the CBF at baseline, SBP at follow-up, and the interval between the first and follow-up PET studies accounted for 10.1%, 5.3% and 11.5% of the variance in changes in the BZR index, respectively. The CBF at baseline, symptom, cerebral ischaemic lesion, ICA disease, hypertension, diabetes mellitus, ischaemic heart disease, hypercholesterolaemia and cigarette use. No significant relationship was found between antihypertensive drug and changes in BZR index values.

Multivariable linear regression analysis was used to investigate the association of changes in the BZR index with (1) CBF at baseline, (2) SBP at follow-up, and (3) the interval between the first and follow-up PET studies (table 3). Our analysis produced a model that included these three independent variables with a correlation coefficient of 0.518 for the changes in the BZR index (p<0.001). In our model, the CBF at baseline, SBP at follow-up, and the interval between the first and follow-up PET studies accounted for 10.1%, 5.3% and 11.5% of the variance in changes in the BZR index, respectively. The CBF at baseline, symptom, cerebral ischaemic lesion, ICA disease, hypertension, diabetes mellitus, ischaemic heart disease, hypercholesterolaemia and cigarette use. No significant relationship was found between antihypertensive drug and changes in BZR index values.
Figure 2 Scatter plot representing systolic blood pressure at follow-up versus changes of the benzodiazepine receptor (BZR) index at follow-up. The black line indicates a regression line for all patients. The dashed lines show the upper 95% limit of changes in the BZR index for the seven controls. CBF, cerebral blood flow.

Table 2 BZR index values for hemispheres ipsilateral or contralateral to arterial disease

|     | Decreased CBF at baseline (n=39) | Normal CBF at baseline (n=37) |
|-----|----------------------------------|-------------------------------|
| Side| Ipsilateral                      | Contralateral                 | Ipsilateral                      | Contralateral                 |
| BZR index at baseline | 40.6±39.2                       | 19.9±21.2                     | 13.2±12.6                       | 8.7±8.7                       |
| BZR index at follow-up | 64.9±65.1*                      | 30.7±28.4                     | 16.7±15.1                       | 12.4±9.1                      |
| BZR index change | 24.2±44.3†                       | 10.7±29.1                     | 3.4±9.8                         | 3.6±9.1                       |

The mean comparative values for BZR index across 10 control subjects or changes of BZR index across seven control subjects were 1.78±1.79 or 0.94±1.38. *P<0.05/4 (using Bonferroni correction) versus baseline value (paired t-test). †P<0.05/2 (using Bonferroni correction) versus corresponding value in the ‘Normal CBF’ group (Student’s t-test).

BZR, benzodiazepine receptor; CBF, cerebral blood flow.

Table 3 Multiple linear regression analysis with changes in the BZR index in the hemisphere with arterial disease as the dependent variable

| Independent variable | Coefficient | SE | Standard coefficient | t | P value |
|----------------------|-------------|----|----------------------|---|---------|
| Baseline CBF (mL/100 g/min) | −1.477 | 0.449 | −0.333 | −3.287 | <0.005 |
| Follow-up SBP (mm Hg) | −0.415 | 0.182 | −0.231 | −2.281 | <0.05 |
| Interval (months) | 0.532 | 0.159 | 0.340 | 3.355 | <0.005 |

BZR, benzodiazepine receptor; CBF, cerebral blood flow; SBP, systolic blood pressure.

At baseline, 41 patients were undergoing treatment via antihypertensive therapies. During follow-up, antihypertensive therapies were discontinued in two patients and started in two patients. SBP at follow-up was positively correlated with changes in the SBP at follow-up (r=0.535; p<0.001). The separate analysis of the data for the 41 patients who were treated for hypertension at baseline showed similar results. Per a simple regression analysis, there was a significant linear relationship between changes in the BZR index and SBP at follow-up (r=−0.350; p<0.05), the interval between the first and follow-up PET studies (r=0.330; p<0.05), or CBF at baseline (r=−0.344; p<0.05). Using multivariable linear regression analysis, the CBF at baseline and SBP at follow-up were significantly correlated with changes in the BZR index, but the interval was not. Our analysis produced a model that included the CBF at baseline and SBP at follow-up with a correlation coefficient of 0.494 for the changes in the BZR index (p<0.005). In our model, the CBF at baseline and SBP at follow-up accounted for 12.1% and 12.3% of the variance in changes in the BZR index, respectively. The relationship between changes in BZR index and SBP differed between patients with decreased CBF at baseline and those without (interaction, p<0.005). Larger significant increases in BZR index values were observed at lower SBP in patients with decreased CBF at baseline (r=−0.573; p<0.02), while smaller and non-significant increases were observed at lower SBP in 22 patients without decreases (r=−0.409; p=0.06).
DISCUSSION

The present study demonstrated an association between low SBP at follow-up and increased damage to cortical neurons in patients with atherosclerotic ICA or MCA disease and no ischemic stroke episodes at follow-up. Selective cortical neuronal damage at follow-up was associated with an increase in BZR index (selective neuronal damage) and SBP differed between patients with decreased CBF at baseline and those without decreases. Patients with decreased CBF at baseline and low SBP appeared to have an elevated risk of subsequent cortical neuronal damage.

In patients with atherosclerotic ICA or MCA disease, chronic reductions in cerebral perfusion pressure increased their risk for cerebral ischemic damage. In patients with haemodynamic impairment, transient decreases in perfusion pressure may reduce perfusion below the penumbra threshold for minutes, which may cause selective neuronal damage without an overt stroke. Low BP might impair the long-term growth of cerebral collaterals. In patients with atherosclerotic ICA or MCA disease and no episodes of ischemic stroke at follow-up, low SBP was associated with haemodynamic deterioration. In agreement with this, here we find that lower SBP was associated with a larger increase in OEF at follow-up, which is indicative of haemodynamic deterioration. Thus, low SBP may be associated with a sustained risk of ischemic neuronal damage due to haemodynamic impairment in patients with atherosclerotic ICA or MCA disease. This may be especially true for patients with decreased CBF at baseline, because only small decreases in perfusion pressure may reduce perfusion below the penumbra threshold. The relationship between BP and the risk of selective neuronal damage in patients with decreased CBF may be different from that in patients without decreased CBF, and lower BP in this specific population may increase the risk of selective neuronal damage.

The separate analysis of the data for the 41 of 76 patients who were treated for hypertension at baseline also demonstrated that decreased SBP at follow-up was associated with increases in cortical neuronal damage at follow-up. Patients with hypertension with decreased CBF at baseline also appear to have an elevated risk of subsequent cortical neuronal damage when SBP at follow-up was low. In patients with antihypertensive therapies, BP levels measured at follow-up might reflect the target goal for BP control. Therefore, low target level of BP achieved might increase the risk of increased selective neuronal damage in such patients with decreased CBF.

The longer interval also contributed to the larger increases of BZR index, as a whole. Follow-up examinations in seven normal subjects, aged 56±8 years, demonstrated no significant change in Z index during follow-up (mean 41±3 months). Therefore, it seems unlikely that only simple ageing contributed to the observed declines in BZR binding over time. The interval was not correlated with changes in the BZR index in patients with hypertension, which suggested that the contribution of haemodynamic fluctuation or deterioration to neuronal damage might be more significant in patients with hypertension treatments than in patients without. We can provide two possible mechanisms other than haemodynamic mechanism due to decline in SBP. First, chronic oligaemia (CBF below 35.0 mL/100 g/min in this study) might cause prolonged inhibition of protein synthesis, which might result in delayed neuronal death. Second, long-term neuronal degeneration secondary to neuronal damage at baseline might develop during follow-up. In patients without hypertension, the effect of these two mechanisms might be stronger than the decline in SBP.

The treatment of hypertension is generally beneficial to patients with atherosclerotic major cerebral artery diseases. However, the level to which BP should be lowered to achieve maximal benefits among patients with atherosclerotic major cerebral artery disease remains unknown. The present study suggests that low SBP may increase the risk of cortical neuronal damage in hemispheres with decreased CBF. It is controversial whether BP controlled to lower levels is associated with a reduced risk of recurrent stroke in patients with atherosclerotic major cerebral artery disease and haemodynamic impairment. Further studies may be required to determine the optimal BP management in patients with atherosclerotic major cerebral artery disease.

The clinical correlations of the decline in BZR binding over time in this sample were unclear from the present study. Some patients developed new cortical symptoms, which were associated with regional cortical neuronal damage, as described previously. Although previous cross-sectional studies have demonstrated selective cortical neuronal damage manifested as a decrease in BZRs, which was associated with subtle cognitive impairment, follow-up studies including systematic neuropsychological tests are needed to correlate variable cortical dysfunction with regional differences of neuronal damage.

Limitations

The present study has some limitations which warrant discussion. First, BP was obtained only during a single visit, which may have led to a misclassification of ongoing BP levels. BP levels measured at follow-up were associated with increases in cortical neuronal damage, while BP levels measured at baseline or averaged at baseline and during follow-up were not. Although the timescale during which selective neuronal damage occurs is unknown, using BP measured during the follow-up period might allow for analysis of the relationship between selective neuronal damage and BP more proximally to the time of an ischemic event. Furthermore, in the present study, we were unable to correct for partial volume effects. Decreases in cortical FMZ binding might at least partly reflect increases in cortical atrophy due to ischemic tissue damage (ie, neuronal loss and partial volume effects), as well as decreases in tissue BZR expression, although we could have more explicitly measured this. It may be ideal that the data are analysed after corrections of PET data for atrophy based on coregistration of MR and PET scans. Lastly, normal control subjects were younger than our patients. Using the reported time-related slopes for CBF versus age (about −6% per decade), the adjusted CBF cut-off values in the present study became 31.6 mL/100 g/min, with an age difference of 16 years between patients and controls. Using this cut-off value, the results in the present study were unchanged (data not shown).

CONCLUSIONS

In patients without ischemic stroke episodes at follow-up but with decreased CBF due to atherosclerotic ICA or MCA disease, low SBP at follow-up may be associated with increases in cortical neuronal damage at follow-up.

Acknowledgements We thank the staff of the Department of Neurology and the Department of Neurosurgery, Shiga General Hospital, for providing clinical assistance.

Contributorship statement HY designed the study, contributed to PET imaging, analysed the data, wrote the first draft of the manuscript and modified all subsequent drafts. SK and CO contributed to PET imaging, contributed to...
interpretation of the data and contributed to all drafts of the manuscript. MT and KK performed PET scanning, analysed the data and contributed to all drafts of the manuscript.

Funding This study was funded by the Japan Society for the Promotion of Science KAKENHI (Grant numbers 17K09814, 26461232).

Competing interests None declared.

Patient consent for publication Not required.

Ethics approval All protocols in this study were approved by the Shiga General Hospital Institutional Review Board, the Human Study Committee. All experiments were performed in accordance with the Declaration of Helsinki and Good Clinical Practice.

Provenance and peer review Not commissioned; externally peer reviewed.

Data availability statement All data relevant to the study are included in the article or uploaded as supplementary information.

Open access This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/.

REFERENCES

1. Baron JC, Bousser MG, Rey A, et al. Reversal of focal “misery-perfusion syndrome” by extra-intracranial arterial bypass in hemodynamic cerebral ischemia. A case study with 123I-iomazenil SPECT study. Stroke 1980;11:454–9.

2. Klijn CJM, Kappelle LJ. Haemodynamic stroke: clinical features, prognosis, and management. Lancet Neurol 2010;9:1008–17.

3. Powers WJ. Cerebral hemodynamics in ischemic cerebrovascular disease. Ann Neurol 1991;29:231–40.

4. Yamauchi H, Higashi T, Kagawa S, et al. Is misery perfusion still a predictor of stroke in symptomatic major cerebral artery disease? Brain 2012;135:2515–26.

5. Garcia IH, Lassen NA, Weiller C, et al. Ischemic stroke and incomplete infarction. Stroke 1996;27:761–5.

6. Baron J-C, Yamauchi H, Fujikoa M, et al. Selective neuronal loss in ischemic stroke and cerebrovascular disease. J Cereb Blood Flow Metab 2014;34:2–18.

7. Ezaj S, Williamson DJ, Ahmed T, et al. Characterizing infarction and selective neuronal loss following temporary focal cerebral ischemia in the rat: a multi-modality imaging study. Neurobiol Dis 2013;51:120–32.

8. Yamauchi H, Kagawa S, Kishibe Y, et al. Progressive cortical neuronal damage and chronic hemodynamic impairment in arterosclerotic major cerebral artery disease. Stroke 2016;47:1534–41.

9. Yamauchi H, Kudoh T, Kishibe Y, et al. Selective neuronal damage and borderzone infarction in carotid artery occlusive disease: a 123I-flumazenil PET study. J Neurol Med 2005;46:1973–9.

10. Yamauchi H, Nishii R, Higashi T, et al. Hemodynamic compromise as a cause of internal border-zone infarction and cortical neuronal damage in arterosclerotic middle cerebral artery disease. Stroke 2009;40:3730–3.

11. Nagaehama T, Fukuyama H, Yamauchi H, et al. Effect of nicardipine on cerebral blood flow in hypertensive patients with internal carotid artery occlusion: a PET study. J Stroke Cerebrovasc Dis 1997;6:325–31.

12. Yamauchi H, Kagawa S, Takahashi M, et al. Long-term hemodynamic changes and blood pressure in arteriosclerotic major cerebral artery disease. J Cereb Blood Flow Metab 2019;39:324–31.

13. Carrera E, Jones PS, Moris RS, et al. Is neural activation within the rescued penumbra impeded by selective neuronal loss? Brain 2013;136:1816–29.

14. Chida K, Ogasawara K, Suga Y, et al. Postoperative cortical neuronal loss associated with cerebral hyperperfusion and cognitive impairment after carotid endarterectomy: 123I-ioflupane SPECT study. Stroke 2009;40:448–53.

15. Yamauchi H, Nishii R, Higashi T, et al. Selective neuronal damage and Wisconsin Card Sorting Test performance in arterosclerotic occlusive disease of the major cerebral artery. J Neurol Neurosurg Psychiatry 2011;82:150–6.

16. Heiss WD, Grond M, Thiel A, et al. Permanent cortical damage detected by flumazenil positron emission tomography in acute stroke. Stroke 1998;29:454–61.

17. Sette G, Baron JC, Young AR, et al. In vivo mapping of brain benzodiazepine receptor changes by positron emission tomography after focal ischemia in the anesthetized baboon. Stroke 1993;24:2046–57.

18. North American Symptomatic Carotid Endarterectomy Trial Collaborators. Beneficial effect of carotid endarterectomy in symptomatic patients with high-grade carotid stenosis. N Engl J Med 1991;325:445–53.

19. Samuels OB, Joseph GJ, Lynn MJ, et al. A standardized method for measuring intracranial arterial stenosis. AJNR Am J Neuroradiol 2000;21:634–6.

20. Okazawa H, Yamauchi H, Sugimoto K, et al. Quantitative comparison of the bolus and steady-state methods for measurement of cerebral perfusion and oxygen metabolism: positron emission tomography study using 15O-gas and water. J Cereb Blood Flow Metab 2001;21:793–803.

21. Okazawa H, Yamauchi H, Sugimoto K, et al. Effects of metabolite correction for arterial input function on quantitative receptor images with 11C-flumazenil in clinical positron emission tomography studies. J Comput Assist Tomogr 2004;28:428–35.

22. Frackowiak RS, Lenzi GL, Jones T, et al. Quantitative measurement of regional cerebral blood flow and oxygen metabolism in man using 15O and positron emission tomography: theory, procedure, and normal values. J Comput Assist Tomogr 1980;4:727–36.

23. Logan J, Fowler JS, Volkow ND, et al. Distribution volume ratios without blood sampling from graphical analysis of PET data. J Cereb Blood Flow Metab 1996;16:834–40.

24. Yamauchi H, Fukuyama H, Kimura J, et al. Hemodynamics in internal carotid artery occlusion examined by positron emission tomography. Stroke 1990;21:1400–6.

25. Kretschmann HJ, Weinich W. Neuroanatomy and cranial computed tomography. New York, NY: Thieme Inc, 1986: 70–4.

26. Minoshima S, Frey KA, Koepp RA, et al. A diagnostic approach in Alzheimer’s disease using three-dimensional stereotactic surface projections of fluorine-18-FDG PET. J Nucl Med 1995;36:1238–48.

27. Mizumura S, Kamita S-Ishio, Cho K, et al. Development of quantitative analysis method for stereotactic brain image: assessment of reduced accumulation in extent and severity using anatomical segmentation. Ann Nucl Med 2003;17:289–95.

28. Schierling W, Troidl K, Mueller C, et al. Increased intravascular flow rate triggers cerebral artiogenesis. J Cereb Blood Flow Metab 2009;29:726–37.

29. Rashid F, Leonardi-Bee J, Bath P. Blood pressure reduction and secondary prevention of stroke and other vascular events: a systematic review. Stroke 2003;34:2741–8.

30. Amin-Hanjani S, Turan NT, Du X, et al. Higher stroke risk with lower blood pressure in hemodynamic verteobasilar disease: analysis from the veritas study. J Stroke Cerebrovasc Dis 2017;26:403–10.

31. Powers WJ, Clarke WR, Grubb RL, et al. Lower stroke risk with lower blood pressure in hemodynamic cerebral ischemia. Neurology 2014;82:1027–32.

32. Yamauchi H, Higashi T, Kagawa S, et al. Impaired perfusion modifies the relationship between blood pressure and stroke risk in major cerebral artery disease. J Neurol Neurosurg Psychiatry 2013;84:1126–32.

33. Yamauchi H, Kagawa S, Kishibe Y, et al. Misery perfusion, blood pressure control, and 5-year stroke risk in symptomatic major cerebral artery disease. Stroke 2015;46:265–8.

34. Marchal G, Riou X, Petit-Taboué MC, et al. Regional cerebral oxygen consumption, blood flow, and blood volume in healthy human aging. Arch Neurol 1992;49:1013–20.